Application of S. waldensis in the preparation of potentiators of immune checkpoint inhibitors

Through the combined use of Waldsatella and immune checkpoint inhibitors, the intestinal microbiota is stimulated, and the problems of limited efficacy and drug resistance in the treatment of tumors are solved, significantly improving the therapeutic effect and response rate.

CN118236407BActive Publication Date: 2024-11-26XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410356830.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-27
Publication Date
2024-11-26
Estimated Expiration
2044-03-27

AI Technical Summary

Technical Problem

The current immune checkpoint inhibitors have limited efficacy in treating tumors, with about 30% of patients not responding to treatment and having high drug resistance, which requires improved treatment sensitivity and efficacy.

Method used

The combination of Waldsarella and immune checkpoint inhibitors is used to enhance the therapeutic effect of immune checkpoint inhibitors by stimulating the anti-tumor immune response of the intestinal microbiota.

Benefits of technology

It significantly improves the therapeutic effect of immune checkpoint inhibitors on multiple tumors, extends the overall survival time of patients, improves the treatment response rate, and expands the beneficiaries of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118236407B_ABST
    Figure CN118236407B_ABST
Patent Text Reader

Abstract

The present invention discloses the use of S. waldensis in the preparation of a synergist of an immune checkpoint inhibitor, and belongs to the field of cancer treatment. The present invention combines S. waldensis with an immune checkpoint inhibitor for the treatment of tumors, and measures the enhanced therapeutic effect by increasing the overall survival time and increasing the progression-free survival period. The results show that S. waldensis can significantly improve the effect of immune checkpoint inhibitors in treating tumors. The present invention is of great significance for improving the overall efficacy of immunotherapy for tumor patients and promoting the transformation and application of drug microbiome in individualized precision medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cancer treatment, and in particular to the use of S. waldensis in the preparation of enhancers of immune checkpoint inhibitors. Background Art

[0002] Malignant tumors are a type of major disease that is fatal and difficult to treat. Recent studies have found that treatment with immune checkpoint inhibitors (ICIs) can significantly prolong the survival of patients with various solid tumors, such as non-small cell lung cancer, melanoma, and renal cell carcinoma. However, only about 30% of patients show definite clinical efficacy to ICIs treatment, and about 60-70% of patients develop primary or secondary drug resistance. Therefore, it is of great clinical significance to identify biomarkers of ICIs response and elucidate their biological mechanisms, and to develop treatment options that can significantly enhance the sensitivity of ICIs.

[0003] The key to improving the overall therapeutic effect of ICIs is to explore biomarkers that determine the clinical efficacy of ICIs using multi-omics (genome, transcriptome, epigenome, metabolome, and microbiome) and design a reasonable ICI combination therapy regimen. This is also one of the key research directions in the current field of pharmacogenomics and personalized precision therapy. PD-L1 expression is currently the most commonly used biomarker to predict the efficacy of ICIs. High PD-L1 expression has been found to be associated with a higher objective response rate in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma who receive PD-1 monoclonal antibodies, but PD-L1 is not applicable to all types of cancer. As a marker for predicting the efficacy of ICIs, it is only applicable to some cancer patients. The spatial heterogeneity of PD-L1 expression and its dynamic evolution with the immune microenvironment reduce its reliability as a biomarker for ICIs treatment.

[0004] The intestinal microbiome has become one of the potential markers for predicting the response to ICIs in tumors. In preclinical models and clinical tumor patients, the composition of intestinal microorganisms is significantly correlated with the efficacy of ICIs. Studies have found that broad-spectrum antibiotics can cause intestinal flora disorders in patients with non-small cell lung cancer, melanoma, etc. treated with ICIs, leading to a significant shortening of the overall survival time (2 months vs 26 months, HR = 7.4), and a significant increase in the non-response rate; higher α diversity of intestinal flora has been shown to be associated with prolonged progression-free survival in melanoma patients receiving ICIs. Fecal microbiota from patients with complete remission (R) after PD-1 monoclonal antibody treatment was transplanted to terminal metastatic melanoma patients with ineffective treatment (NR). About 30% of the recipient patients (NR) had new significant clinical responses, of which 10% even had complete remission. High abundance of Fusobacterium nucleatum (F. nucleatum) in the intestine is associated with a good response to PD-1 monoclonal antibody treatment in colorectal cancer patients. B. pseudolongum isolated from mice with orthotopic colon cancer that respond well to ICIs can promote the anti-colorectal cancer effect of PD-1 monoclonal antibody through its metabolite creatinine. This shows that intestinal flora has an important influence on the efficacy of ICIs in the treatment of colorectal cancer, melanoma, non-small cell lung cancer and other malignant tumors, and specific intestinal flora may become a new class of biomarkers for predicting the responsiveness of ICIs treatment.

[0005] The intestinal flora and its metabolites can improve the responsiveness of ICIs treatment by regulating the body's innate immunity and adaptive immunity. In terms of innate immune regulation, the intestinal flora can affect the functions of dendritic cells (DCs), monocytes and macrophages, and natural killer cells (NK). For example, A. muciniphila can activate the TLR2 / NF-κB and NLRP3 pathways and induce macrophages to polarize to the M1 type, thereby inhibiting the progression of colon cancer. Lactobacillus rhamnousus GG (LGG) induces the secretion of IFN-β by activating the cGAS / STING / TBK1 / IRF1 signaling pathway in DCs, thereby improving the anti-tumor effect of PD-1 monoclonal antibodies. In terms of adaptive immune regulation, the intestinal flora can affect CD8 + T and CD4 + The intestinal microbiota metabolite butyrate directly enhances CD8 T cell activity through inhibitory DNA binding 2 (ID2)-IL-12 +The tumor killing effect of T cells; the secondary metabolite inosine of Bifidobacterium pseudolongum (B. pseudolongum) activates the phosphorylation of cAMP response element binding protein (pCREB) through the T cell-specific A2AR-cAMP-PK4 signaling pathway, upregulates the transcription of IL12Rβ2 and IFNγ, activates the Th1 cell immune response, and thus enhances the efficacy of ICIs. Therefore, in-depth exploration of the functional characteristics of different types of intestinal flora and their metabolites is crucial to identify the mechanism of anti-tumor immunotherapy response and improve the efficacy of ICIs. Summary of the invention

[0006] The purpose of the present invention is to provide the use of S. waldensis in the preparation of an enhancer of an immune checkpoint inhibitor, so as to solve the problems existing in the above-mentioned prior art. By using S. waldensis in combination with an immune checkpoint inhibitor, the effect of the immune checkpoint inhibitor in treating tumors can be significantly improved.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides the use of Sutterella wadsworthensis in preparing a synergist of an immune checkpoint inhibitor for tumor treatment.

[0009] The present invention also provides the use of Waldersartella combined with immune checkpoint inhibitors in the preparation of drugs for treating tumors.

[0010] The tumor treatment includes reduction or stabilization of tumor volume, extension of overall survival time of tumor patients, extension of progression-free survival period, and improvement of quality of life.

[0011] Preferably, the Sutterella wadsworthensis comprises a 16S rDNA sequence, and the Sutterella wadsworthensis of the present invention refers to any strain having at least 99% identity with the 16S rDNA sequence of Sutterella wadsworthensis. More preferably, the Sutterella wadsworthensis is a combination of one or more Sutterella wadsworthensis strains. More preferably, the Sutterella wadsworthensis strain is a strain of the genome database of the National Center for Biotechnology Information (NCBI) of the United States. https: / / www.ncbi.nlm.nih.gov / genome / browse / #! / prokaryotes / Sutterella%20wadsworthensis) The strain names of the Central Asian subspecies classification are: Sutterella wadsworthensis DSM14016, Sutterella wadsworthensis FDAARGOS_1159, Sutterella wadsworthensis 351h, Sutterella wadsworthensis 809h, Sutterella wadsworthensis 351h, Sutterellawadsworthensis DFI.4.78, Sutterella wadsworthensis 934h, Sutterellawadsworthensis MCC752, Sutterella wadsworthensis 239h, Sutterellawadsworthensis 333h, Sutterella wadsworthensis 228h, Sutterella wadsworthensis1122h, Sutterella wadsworthensis HGA0223, Sutterella wadsworthensis 3_1_45B, Sutterella wadsworthensis 2_1_59BFAA, Sutterella wadsworthensis min17_bin46, Sutterella wadsworthensis CD33_MAG38, Sutterella wadsworthensis UBA11514, Sutterella wadsworthensis UBA11458, Sutterella wadsworthensis UBG025, Sutterella wadsworthensis SUG770, Sutterella wadsworthensis 1017h, Sutterellawadsworthensis 1045h, Sutterella wadsworthensis 2733h, Sutterellawadsworthensis 3358, Sutterella wadsworthensis 876h, Sutterella wadsworthensis831h, Sutterella wadsworthensis 856h, Sutterellawadsworthensis 830h, Sutterella wadsworthensis 877h, Sutterella wadsworthensis 910h, Sutterella wadsworthensis 627h, Sutterella wadsworthensis UBA10685 and Sutterella wadsworthensis 823h, or a combination thereof. More preferably, the wadsworthensis strain is one or a combination of the following strains: wadsworthensis deposited in the German DSM collection of microorganisms and cell cultures with a deposit number of DSM 14016 (NCBI: taxid 40545, https: / / www.ncbi.nlm.nih.gov / datasets / taxonomy / tree / ?taxon=40545 ); Waldesartella deposited in the American ATCC Type Culture Collection with the accession number ATCC 51579; Waldesartella deposited in the Japan Collection of Microorganisms with the accession number JCM32440; Waldesartella deposited in the Korean Collection for Type Cultures with the accession number KCTC 15691; Waldesartella deposited in the Swedish CCUG Culture Collection (Culture Collection University of Gothenburg) with the accession number CCUG 69352; Waldesartella deposited in the French CIP Culture Collection (Culture Collection University of Gothenburg) with the accession number CIP 104799; Waldesartella deposited in the British NCTC Culture Collection (National Collection of Type Cultures) with the accession number NCTC The present invention is described by taking the Wardersartella with the deposit number DSM 14016 as an example.

[0012] The immune checkpoint inhibitor is a combination of one or more blockers acting on T cell negative co-stimulation (co-inhibition) molecules and / or their respective ligands. It is preferred that T cell negative co-stimulation (co-inhibition) molecules and / or their respective ligands are selected from CTLA-4, PD-1, PD-L1, PD-L2, B7-1, B7-2, B7-H3, B7-H4, B7-H6, A2AR, IDO, TIM-3, BTLA, VISTA, TIGIT, LAG3, CD40, KIR, CEACAM1, GARP, PS, CSF1R, CD94 / NKG2A, TDO, TNFR, DcR3.More preferably, the blocker of the ligand of the negative co-stimulatory (co-inhibitory) molecule of T cells is selected from nivolumab (PD-1 monoclonal antibody), ipilimumab (CTLA-4 monoclonal antibody), pembrolizumab (PD-1 monoclonal antibody), azetolizumab (PD-L1 monoclonal antibody), atezolizumab (PD-L1 monoclonal antibody), camrelizumab (PD-L1 monoclonal antibody), tislelizumab (BGB-A317), durvalumab (durvalumab , PD-L1 monoclonal antibody), tremelimuab (CTLA-4 monoclonal antibody), spartalizumab (PD-L1 monoclonal antibody), avelumab (PD-L1 monoclonal antibody), sintilimab (PD-1 monoclonal antibody), toripalimab (PD-L1 monoclonal antibody), cemiplimab (PD-1 monoclonal antibody), MGA012 (retifanlimab, PD-1 monoclonal antibody), MGD013 (tebotelimab, PD-1 / LAG-3 dual antibody), MGD019 (PD-1 / CTLA-4 dual antibody), enoblituzumab (B7-H3 monoclonal antibody), MGD009 (B7-H3 monoclonal antibody), MGC018 (B7-H3 monoclonal antibody), MEDI0680 (PD-1 monoclonal antibody), PDR001 (PD-1 monoclonal antibody), FAZ053 (PD-L1 monoclonal antibody), TSR022 (TIM-3 monoclonal antibody), MBG453 (TIM-3 monoclonal antibody), relatlimab (BMS986016, LAG-3 monoclonal antibody), LAG525 (LAG-3 monoclonal antibody), IMP321 (LAG-3 monoclonal antibody), REGN3767 (LAG-3 monoclonal antibody), pexidatinib (pexidatinib), rtinib, GSF-1R monoclonal antibody), LY3022855 (CSF-1R monoclonal antibody), FPA008 (CSF-1R monoclonal antibody), BLZ945 (CSF-1R monoclonal antibody), GDC0919 (navoximod, IDO monoclonal antibody), epacadostat (IDO monoclonal antibody), indoximid (IDO monoclonal antibody), BMS986205 (IDO monoclonal antibody), CPT-444 (A2AR monoclonal antibody), MEDI9447 (oleclumab, CD73 monoclonal antibody), PBF509 (A2AR monoclonal antibody), lirilumab (KIR monoclonal antibody) or any combination thereof.More preferably, the blocker is selected from nivolumab, pembrolizumab, toripalimab, sintilimab, cemiplimab or any combination thereof. More preferably, the immune checkpoint inhibitor is an inhibitor acting on the PD-1 / PD-L1 signaling pathway and / or the PD-1 / PD-L2 signaling pathway, wherein PD-1 refers to programmed death protein 1, also known as CD279, and PD-L1 (B7-H1 or CD274) and PD-L2 (B7-DC or CD273) are ligands of PD-1. More preferably, the inhibitor of the PD-1 / PD-L1 signaling pathway or the PD-1 / PD-L2 signaling pathway is selected from nivolumab (PD-1 monoclonal antibody), perbrolizumab (PD-1 monoclonal antibody), azetolizumab (PD-L1 monoclonal antibody), atezolizumab (PD-L1 monoclonal antibody), camrelizuman (PD-L1 monoclonal antibody), tislelizumab (BGB-A317), durvalumab (PD-L1 monoclonal antibody), spartalizumab (PD-L1 monoclonal antibody), and spartalizumab (PD-L1 monoclonal antibody). umab (PD-1 monoclonal antibody), avelumab (PD-L1 monoclonal antibody), sintilimab (PD-1 monoclonal antibody), toripalimab (PD-1 monoclonal antibody), cemiplimab (PD-1 monoclonal antibody), MGA012 (retifanlimab, PD-1 monoclonal antibody), MGD013 (tebotelimab, PD-1 / LAG-3 dual antibody), MGD019 (PD-1 / CTLA-4 dual antibody), MEDI0680 (PD-1 monoclonal antibody), PDR001 (PD-1 monoclonal antibody), FAZ053 (PD-L1 monoclonal antibody) or any combination thereof. More preferably, the immune checkpoint inhibitor is an inhibitor acting on the CTLA-4 / B7-1 signaling pathway and / or the CTLA-4 / B7-2 signaling pathway, wherein CTLA-4 refers to cytotoxic T lymphocyte protein 4, also known as CD152, B7-1 (CD80) and B7-2 (CD86) are ligands of CTLA-4. More preferably, it can be selected from ipilimumab (CTLA-4 monoclonal antibody), tremelimumab (CTLA-4 monoclonal antibody), MGD019 (PD-1 and CTLA-4 dual antibody) or any combination thereof.As a specific embodiment of the present invention, the immune checkpoint inhibitor is an inhibitor acting on the PD-1 / PD-L1 signaling pathway and / or the PD-1 / PD-L2 signaling pathway and / or an inhibitor acting on the CTLA-4 / B7-1 signaling pathway and / or the CTLA-4 / B7-2 signaling pathway. Specifically, the immune checkpoint inhibitor is a PD-1 monoclonal antibody or a CTLA-4 monoclonal antibody.

[0013] Preferably, the tumor includes a reduction or stabilization of tumor volume, a prolonged overall survival time of tumor patients, a prolonged progression-free survival period, and an improved quality of life.

[0014] Preferably, the tumor is an adenoma, a malignant tumor and adenocarcinoma, wherein the tumor is classified according to the tissue origin or cell name, including: bladder urothelial carcinoma, adrenocortical carcinoma, breast cancer, pancreatic cancer, cervical cancer, bile duct cancer, colon cancer, colorectal cancer, diffuse large B-cell lymphoma, multiform glioma, glioma, head and neck cancer, renal chromophobe cell carcinoma, mixed nerve cancer, renal cancer, leukemia, lymphoma, brain cancer, liver cancer, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian cancer, pancreatic cancer, pheochromocytoma, paraganglioma, prostate cancer, rectal adenocarcinoma, sarcoma, skin melanoma, gastric cancer, esophageal cancer, testicular cancer, thyroid cancer, thymic cancer, endometrial cancer, uterine sarcoma, uveal melanoma and soft tissue sarcoma one or more. As a specific embodiment of the present invention, the tumor is colorectal cancer. Preferably, the tumor is a malignant tumor, a metastatic tumor or a non-metastatic tumor. More preferably, any stage of cancer is included (clinical stage I, II, III, or IV, TNM classification of malignant tumors T1-4, N0-4 or M0-1, histological grade G1, G2, G3 or G4, etc.).

[0015] The present invention also provides the use of a pharmaceutical composition or preparation containing Waldersartella in the preparation of a synergist of an immune checkpoint inhibitor for tumor treatment.

[0016] Preferably, the Waldersartella is a combination of one or more Waldersartella strains (as described above). As an embodiment of the present invention, the deposit number of Waldersartella is DSM NO: 14016, and the immune checkpoint inhibitor includes PD-1 monoclonal antibody, PD-L1 monoclonal antibody or CTLA-4 monoclonal antibody.

[0017] Preferably, the pharmaceutical composition or the preparation uses the Wardersartella as an active ingredient, and the Wardersartella is a live bacterium;

[0018] The pharmaceutical composition or the preparation also includes a pharmaceutically acceptable carrier and excipient. The term "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce adverse reactions, allergic reactions or other unfavorable reactions when used in animals (e.g., humans, if appropriate). A specific example of a pharmaceutically acceptable carrier as described in the present invention is a borate buffer or a sterile saline solution.

[0019] Preferably, the pharmaceutical composition is prepared into tablets, capsules, granules, suspensions or injections.

[0020] Preferably, the tumor includes one or more of bladder urothelial carcinoma, adrenocortical carcinoma, breast cancer, pancreatic cancer, cervical cancer, bile duct cancer, colon cancer, colorectal cancer, diffuse large B-cell lymphoma, multiforme glioma, glioma, head and neck cancer, renal chromophobe cell carcinoma, mixed nerve carcinoma, kidney cancer, leukemia, lymphoma, brain cancer, liver cancer, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian cancer, pancreatic cancer, pheochromocytoma, paraganglioma, prostate cancer, rectal adenocarcinoma, sarcoma, skin melanoma, gastric cancer, esophageal cancer, testicular cancer, thyroid cancer, thymic cancer, endometrial cancer, uterine sarcoma, uveal melanoma and soft tissue sarcoma.

[0021] The present invention also provides a pharmaceutical composition or preparation for treating tumors, comprising an effective dose of Waldersartella combined with an immune checkpoint inhibitor, wherein the deposit number of the Waldersartella is DSM NO: 14016, and the immune checkpoint inhibitor comprises PD-1 monoclonal antibody, PD-L1 monoclonal antibody or CTLA-4 monoclonal antibody.

[0022] The present invention proposes a combination therapy: immune checkpoint inhibition therapy is performed simultaneously, separately or sequentially with the use of S. waldensis, thereby increasing the therapeutic effect of immune checkpoint inhibition.

[0023] The administration route for using Waldersartella is oral.

[0024] The order of using the combination therapy is: using the said Waldersartella simultaneously with, before and / or after the immune checkpoint inhibition therapy.

[0025] In the combination therapy, dose delays and / or dose reductions and time adjustments are performed as needed based on the individual patient's tolerance to the treatment.

[0026] The Waldersartella described in the present invention may include an effective amount of Waldersartella generally dispersed in a pharmaceutically or pharmacologically acceptable carrier.

[0027] The term "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered to animals (e.g., humans, if appropriate). Specific examples of pharmacologically acceptable carriers as described herein are borate buffer or sterile saline solution.

[0028] The enhanced immune checkpoint inhibitors of the present invention can be used for patients who are refractory to immune checkpoint inhibitors, wherein the patients who are refractory to immune checkpoint inhibitors exhibit innate (primary) resistance to treatment with the immune checkpoint inhibitors, which is manifested as a lack of response or insufficient response to treatment with the checkpoint inhibitors that lasts for at least about 8 weeks or 12 weeks from the first dose.

[0029] The enhanced immune checkpoint inhibitors described in the present invention can be used for patients who are refractory to immune checkpoint inhibitors, wherein the patients who are refractory to immune checkpoint inhibitors show acquired (secondary) resistance to treatment with multiple checkpoint inhibitors, which is manifested as an initial response to the checkpoint treatment, but one or more tumors subsequently recur and develop.

[0030] The present invention discloses the following technical effects:

[0031] The present invention relates to a combined therapy for enhancing the efficacy of immune checkpoint inhibitors, which is suitable for colorectal cancer and other tumors. The present invention uses S. waldensis as a new type of immune adjuvant in combination with ICIs for tumor treatment to achieve significant technical effects, providing a scientific basis for the combined therapy of bacteria and ICIs, and providing a new solution for improving the clinical efficacy of ICIs with intestinal microorganisms as targets, which is of great significance for improving the overall efficacy of immunotherapy for tumor patients and promoting the transformation and application of drug microbiome in individualized precision medicine.

[0032] The present invention uses an oral preparation of a human symbiotic bacterium (Serratia waldenii) in combination with an immune checkpoint inhibitor. The anti-tumor immune protection response stimulated by Serratia waldenii significantly enhances the efficacy of immune checkpoint inhibitors against a variety of tumors with higher safety, prolongs the overall survival time of tumor patients, increases the response rate of the cancer immunotherapy population, and expands the population of tumor patients who benefit from cancer immunotherapy (immunotherapy checkpoint inhibitors). BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0034] Figure 1 It is the experimental flow chart of Example 1;

[0035] Figure 2 Tumor volume change curve; MC38 tumor model (left), CT26 tumor model (right);

[0036] Figure 3 Statistical graph of tumor weight; MC38 tumor model (left), CT26 tumor model (right);

[0037] Figure 4 HE staining of intestinal tissue (day 19) of MC38 tumor model mice;

[0038] Figure 5 The results of multicolor flow cytometry staining of mouse tumor tissue at the experimental endpoint; CD4 + ICOS+T(A),CD8 + IFN-γ+TNF-α+T(B),CD4 + The proportion of IFN-γ+TNF-α+T(C) cells; CD8 + IFN-γ+TNF-α+T(D),CD4 + IFN-γ+TNF-α+T(E) cell ratio;

[0039] Figure 6 RNA-seq results of tumor tissues (day 19) of MC38 tumor model mice;

[0040] Figure 7 The distribution and relative abundance of Waldersartella in different populations;

[0041] Figure 8 is the relationship between the abundance of S. waldensis and the efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma; A is progression-free survival; B is the treatment effect, where SD is stable disease, CR is complete remission, PD is progressive disease, and PR is stable disease. DETAILED DESCRIPTION

[0042] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0043] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0044] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0045] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0046] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0047] The present invention significantly improves the problems of conventional therapies, such as large toxic and side effects, easy recurrence and metastasis, short duration of therapeutic effect, short patient survival, heavy economic burden and poor quality of life; significantly improves the shortcomings of immune checkpoint monotherapy, such as small number of drug-responsive population and small number of effective tumor types; and significantly improves the shortcomings of immune checkpoint combined with chemoradiotherapy, such as severe adverse reactions and limited drug-responsive population.

[0048] The treatment regimen provided by the present invention has a good therapeutic effect on the following patients: patients who cannot undergo surgery, have no effectively available targeted drugs, and are ineffective with radiotherapy and chemotherapy; patients with tumors for which immune checkpoint inhibitors alone are ineffective or have developed drug resistance (primary, adaptive, and acquired); patients with tumors for which immune checkpoint inhibitors combined with radiotherapy, chemotherapy, and targeted therapy are ineffective or have developed drug resistance (primary, adaptive, and acquired).

[0049] The treatment scheme provided by the present invention is further described below with reference to specific embodiments.

[0050] Example 1 The therapeutic effect of S. waldensis combined with immune checkpoint inhibitors on tumors

[0051] 1. Experimental methods

[0052] 1.1 Experimental Materials

[0053] (1) Mouse strains: 6-week-old female C57BL / 6J mice and Balb / c mice.

[0054] (2) Tumor cell lines: mouse colorectal cancer cell line (MC38, ATCC), mouse colorectal cancer cell line (CT26, ATCC).

[0055] (3) Bacterial preparation: Sutterella wadsworthensis (DSM NO: 14016, Type strain, whose 16S rDNA sequence is shown in SEQ ID NO: 1), referred to as SW, was purchased from DSMZ German National Culture Collection (the official website of DSMZ is: http: / / www.dsmz.de ).

[0056] (4) Bacterial culture medium: liquid mGAM medium, the formula mainly includes peptone, yeast extract, soluble starch, beef extract and glucose, etc., purchased from Nissui Pharmaceutical Co., Ltd., Japan. Fumaric acid (2.86 g / L) and formate (2.86 g / L) were additionally added to this medium.

[0057] (5) Immune checkpoint inhibitors: PD-1 monoclonal antibody (αPD-1), clone number RPM1-14, the reagent was purchased from BioXCell, USA.

[0058] (6) Antibiotic combination: ampicillin (50 mg / kg), neomycin sulfate (50 mg / kg), vancomycin (25 mg / kg), and metronidazole (50 mg / kg).

[0059] 1.2 Experimental Grouping

[0060] The experimental groups are shown in Table 1 below.

[0061] Table 1

[0062]

[0063]

[0064] 1.3 Experimental methods

[0065] The experimental flow chart is shown in Figure 1 , the specific operations are as follows:

[0066] (1) Bacterial culture: Inoculate Waldersartella in mGAM liquid medium (containing formate and fumaric acid), culture at 37°C in an anaerobic chamber for 48 hours, and then centrifuge to a concentration of 1×10 9 CFU / mL.

[0067] (2) Subcutaneous inoculation of tumor cells: MC38 cell line 5×10 5 / mouse, CT26 cell line 5×10 5 / Only.

[0068] (3) 14 to 8 days before tumor cell inoculation: Each group of mice was intragastrically administered with a combination of antibiotics to eliminate the intestinal flora.

[0069] (4) 7 to 16 days before tumor cell inoculation: SW live bacterial liquid preparation treatment was given by gavage, 100 μL / mouse, 1×10 8 CFU / piece.

[0070] (5) IgG or PD-1 mAb was injected intraperitoneally on days 7, 10, 13, and 16, 200 μg per mouse.

[0071] (6) Tumor size was measured on days 7, 10, 13, 16, and 18, and the tumor volume was calculated.

[0072] Tumor volume = (tumor width 2 × tumor long diameter) × 1 / 2

[0073] (7) On the 18th day, the mice were euthanized, the tumor tissues were removed, photographed and weighed, and the intestinal tissues were taken for HE staining to determine the status of intestinal inflammation.

[0074] (8) The tumor volume and weight of mice were measured at the end time point, and multi-color flow cytometry was used to evaluate the infiltration of immune cells in tumor tissues for efficacy evaluation.

[0075] (9) HE staining of mouse intestinal tissue sections was used to evaluate whether Waldersartella can cause enteritis for safety assessment.

[0076] 2. Experimental results

[0077] like Figure 2 and Figure 3 As shown, they are the tumor volume change curve and tumor weight statistics, respectively. The results show that in the MC38 and CT26 colorectal cancer mouse models, compared with the placebo treatment group (IgG) and the single-agent immune checkpoint inhibitor group (PD-1mAb), the combination therapy group (PD-1mAb+SW) showed obvious and significant tumor reduction (p<0.01), proving that S. waldensis can enhance the anti-tumor effect of PD-1mAb.

[0078] like Figure 4 As shown, it is the HE staining result of intestinal tissue section of MC38 mouse model at the experimental endpoint. The results show that no enteritis was found in mice in the Waldensia single bacteria group (IgG+SW) and the combination therapy group (PD-1mAb+SW), proving the safety of oral gastrointestinal administration of Waldensia.

[0079] like Figure 5 As shown, it is the experimental end point MC38 ( Figure 5 AC) and CT26( Figure 5 The results of multicolor flow cytometry staining of mouse tumor tissue in DE) showed that the single-bacteria group of Waldersartella (IgG+SW) could significantly increase the infiltration of CD4+ICOS+T cells in tumor tissue. Compared with the single-drug immune checkpoint inhibitor group (PD-1mAb), the combined therapy group (PD-1mAb+SW) also had significantly increased CD4 + ICOS+T cell infiltration; at the same time, it was observed in both MC38 and CT26 mouse tumor models that compared with the single-agent immune checkpoint inhibitor group (PD-1mAb), the combination therapy group (PD-1mAb+SW) had increased CD8 + IFN-γ+TNF-α+and CD4 + IFN-γ+TNF-α+T cells confirmed that S. waldensis could enhance the anti-tumor immune response of PD-1 mAb. Compared with the placebo treatment group (IgG), the S. waldensis single bacteria group (IgG+SW) showed an increase in tumor CD8 + IFN-γ+TNF-α+T cells and CD4 + The trend of IFN-γ+TNF-α+T cell infiltration confirmed the regulatory effect of oral administration of S. waldensis on systemic immunity.

[0080] like Figure 6 As shown, it is the RNA-seq result of mouse tumor tissue. The results show that compared with the single-agent immune checkpoint inhibitor group (PD-1mAb), the combination therapy group (PD-1mAb+SW) showed activated anti-tumor immune response signals, indicating that oral administration of S. waldensis significantly enhanced the anti-tumor immune response during immune checkpoint inhibitor treatment.

[0081] Example 2: Waldersartella is an endogenous intestinal commensal bacterium in humans

[0082] 1. Experimental methods

[0083] The human intestinal metagenomic dataset was analyzed using the GMrepo public database, which contained a total of 2,676 human fecal samples from 14 different types of people. Metagenomic sequencing technology can achieve the accuracy of identifying human intestinal bacteria at the species level.

[0084] The 14 different types of populations include: 1) healthy people; 2) diarrhea; 3) inflammatory bowel disease; 4) colorectal cancer; 5) autism spectrum disorder; 6) cirrhosis; 7) cardiovascular disease; 8) type 1 diabetes; 9) rheumatoid arthritis; 10) type 2 diabetes; 11) non-alcoholic fatty liver disease; 12) Parkinson's disease; 13) hypertension; 14) gut microbiota metagenomics data of renal cell carcinoma patients before treatment with immune checkpoint inhibitors (ICIs).

[0085] The sample sizes of the relevant population types included are shown in Table 2.

[0086] Table 2 Human intestinal metagenomic public datasets

[0087]

[0088]

[0089] 2. Experimental results

[0090] like Figure 7 As shown in Table 3, the results show that Sutterella wadsworthensis exists in different populations, with a relative abundance of 0.47% to 12.5%, and there are differences in the relative abundance of Sutterella wadsworthensis in different populations, where the relative abundance refers to the proportion of a certain species to all bacterial species in the intestine. According to the total number of bacterial species in the human intestine, which is about 10 14 According to the estimation of CFU / mL, the number of Waldersartella in the human intestine is about 10 11 CFU / mL~10 13 CFU / mL.

[0091] Table 3 Relative abundance of S. waldensis in different populations

[0092]

[0093] Example 3 Intestinal abundance of S. waldensis is associated with responsiveness to ICIs in patients with renal cell carcinoma

[0094] 1. Experimental methods

[0095] The public intestinal metagenomic dataset PRJEB 22863 of patients with renal cell carcinoma (RCC) was analyzed, which contained 62 stool samples of patients with renal cell carcinoma (RCC) before treatment with immune checkpoint inhibitors (ICIs). The relationship between the baseline fecal abundance of Sutterella wadsworthensis in RCC patients and the responsiveness of patients to ICIs treatment was established.

[0096] 2. Experimental results

[0097] like Figure 8 As shown, the results showed that patients with renal cell carcinoma with high abundance of Sutterella wadsworthensis in the intestine had a higher proportion of progression-free survival (PFS) greater than or equal to 6 months, better disease control, and higher response rate.

[0098] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Waldersartella Sutterella wadsworthensis ) in the preparation of a synergist of an immune checkpoint inhibitor for tumor treatment, characterized in that: The deposit number of the Waldenstromella is DSM NO: 14016, the immune checkpoint inhibitor is PD-1 monoclonal antibody, the tumor is colon cancer, and the Waldenstromella is a live bacterium.

2. Use of S. waldensis combined with immune checkpoint inhibitors in the preparation of drugs for treating tumors, characterized in that: The deposit number of the Waldenstromella is DSM NO: 14016, the immune checkpoint inhibitor is PD-1 monoclonal antibody, the tumor is colon cancer, and the Waldenstromella is a live bacterium.

3. Use of a pharmaceutical composition or preparation containing S. waldensis in the preparation of a synergist of immune checkpoint inhibitors for tumor treatment, characterized in that: The deposit number of the Waldenstromella is DSM NO: 14016, the immune checkpoint inhibitor is PD-1 monoclonal antibody, the tumor is colon cancer, and the Waldenstromella is a live bacterium.

4. The use according to claim 3, characterized in that The pharmaceutical composition or the preparation contains the Waldersartella as an active ingredient; The pharmaceutical composition or the preparation further comprises pharmaceutically acceptable carriers and excipients.

5. The use according to claim 3, characterized in that The pharmaceutical composition is prepared into tablets, capsules, granules, suspensions or injections.

6. A pharmaceutical composition or preparation for treating tumors, characterized in that: It comprises an effective dose of Waldersartella combined with an immune checkpoint inhibitor, the deposit number of the Waldersartella is DSM NO: 14016, the immune checkpoint inhibitor is PD-1 monoclonal antibody, the tumor is colon cancer, and the Waldersartella is a live bacterium.

Citation Information

Patent Citations

  • Microbiota composition, as a marker of responsiveness to Anti-PD1 / PD-l1 / PD-l2 antibodies in renal cell cancer

    CN113287016A

  • Methods and compositions for treating cancer

    CN113645981A

  • Application of bacteria in preparation of synergist of immune checkpoint inhibitor

    CN114159475A

  • Use of immunotherapy and microbiome modulation to treat cancer

    WO2022178193A2

  • Compositions and methods for determining responsiveness to immune checkpoint inhibitors (ICI), increasing effectiveness of ici, and treating cancer

    WO2022261382A1